Related Experiment Video
Updated: Jun 23, 2026
08:53
Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Drug development for recurrent and refractory classical Hodgkin lymphoma
Tanya M Wildes1, Nancy L Bartlett
1Division of Geriatrics and Nutritional Science, Washington University School of Medicine, St Louis, MO 63110, USA. twildes@dom.wustl.edu
Leukemia & Lymphoma
|April 18, 2009
Summary
Classical Hodgkin lymphoma (cHL) is treatable, but relapsed disease after transplant has a poor prognosis. New targeted therapies and immunotherapies show promise for these patients.
Area of Science:
- Oncology
- Hematology
- Immunotherapy
Background:
- Classical Hodgkin lymphoma (cHL) is generally treatable with initial chemotherapy or combined modality therapy.
- High-dose therapy with autologous stem cell transplant is the standard for relapsed disease.
- Prognosis is poor for patients relapsing post-transplant or ineligible for transplant, necessitating novel strategies.
Purpose of the Study:
- To review current and emerging targeted therapies for relapsed Hodgkin lymphoma.
- To highlight promising treatment avenues for patients with poor prognoses.
Main Methods:
- Review of targeted therapies including monoclonal antibodies, immunoconjugates, and bispecific constructs.
- Discussion of radioimmunotherapy and T-cell therapies targeting Epstein-Barr virus (EBV) in EBV-associated cHL.
- Exploration of immunomodulatory agents (thalidomide, lenalidomide) and novel drug classes (mTOR inhibitors, HDAC inhibitors).
Main Results:
- Monoclonal antibodies, immunoconjugates, and bispecific constructs offer targeted approaches.
- T-cell therapies show potential in EBV-associated cHL.
- Immunomodulatory agents and novel drug classes demonstrate promise in preclinical and early clinical studies.
Conclusions:
- Significant progress is being made in developing targeted therapies for relapsed Hodgkin lymphoma.
- These novel agents offer hope for patients with poor prognoses, particularly those who have relapsed after transplant.
- Further clinical investigation is warranted to establish the efficacy and safety of these emerging treatments.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...